OptiNose (OPTN) Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Optinose (OPTN) PT Lowered to $9 at BMO Capital
November 17, 2021 9:08 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Optinose (NASDAQ: OPTN) to $9.00 (from $16.00) while maintaining an Outperform rating.
The analyst commented, "3Q Xhance revenue was slightly below and 2021 guidance lowered given continued COVID-19 headwinds impacting sales access and Rx volumes (though... More
OptiNose (OPTN) Prices 25M Share Offering at $1.60/sh
November 16, 2021 8:02 AM ESTOptinose (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $1.60 per share, for gross proceeds of $40.0 million to Optinose, before deducting underwriting discounts and before offering expenses. All shares of common stock in the offering are being offered by Optinose. In addition, Optinose has granted the underwriters an option for a period of 30 days to purchase up to an additional 3,750,000 shares at the public... More
